Double-blind experiments on the effect of a peanut extract on the bleeding incidence in 92 haemophiliacs.

Verstraete, Marc; Ruys, Caj

doi:10.1136/bmj.4.5577.453

Cited by 11 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An in vivo study by Hvas et al showed that a combination of TXA and Factor VIII (FVIII) improved clot stability when compared with FVIII alone [14]. The use of antifibrinolytic agents in haemophilia most probably finds its origins in the observation by a haemophilic patient that consumption of roasted peanuts reduced tenderness in acute haemarthrosis [17]. Some authors have described possibility of using peanuts or peanut extracts to increase antifibrinolytic potential, although this is not based on trials [15][16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-fibrinolytic agents in bleeding disorders – A clinical perspective

Hart

Badle

2016

The Journal of Haemophilia Practice

View full text Add to dashboard Cite

Tranexamic acid (TXA) is a synthetic antifibrinolytic drug used widely used to control bleeding complications in a wide variety of clinical situations. Soon after its development in the 1960s it found use in treatment of women with menorrhagia, and in inherited bleeding disorders. Subsequently it was used in surgery and with proven efficacy to reduce transfusion requirements and bleeding complications. Recent meta-analysis have provided further evidence of efficacy and safety. Tranexamic acid is now on the World Health Organization’s (WHO) list of essential drugs, and is the focus of ongoing worldwide trials. Similarly, there is increasing evidence base in both congenital and acquired bleeding disorders. We present a clinical narrative of the antifibrinolytic system and associated drugs to accompany the pharmacy review by Chaplin et al, with the aim of highlighting the evolution of TXA use in bleeding disorders over recent decades.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Some authors have described possibility of using peanuts or peanut extracts to increase antifibrinolytic potential, although this is not based on trials [15][16]. Verstraete et al demonstrated peanut oil to have no statistically proven benefit in 92 haemophiliacs in a double-blinded trial [17].…”

Section: Discussionmentioning

confidence: 99%

Anti-fibrinolytic agents in bleeding disorders – A clinical perspective

Hart

Badle

2016

The Journal of Haemophilia Practice

View full text Add to dashboard Cite

show abstract

“…However, its efficacy was disputed and in 1967, a double-blind study involving 92 hemophiliacs concluded that no statistical benefits on bleeding incidence could be observed using peanut-based therapy. 12 A major breakthrough in hemophilia A treatment arrived with the discovery of cryoprecipitate by Dr. Judith Pool. 13 This demonstrated the high potential of factor VIII (FVIII) to be available in a concentrated manner, which enabled the development of FVIII concentrates of increasing purity.…”

Section: History Of Hemophilia a Treatmentmentioning

confidence: 99%

Emerging Therapeutic Strategies in the Treatment of Hemophilia A

Muczynski

Olivier

Denis

et al. 2017

Semin Thromb Hemost

View full text Add to dashboard Cite

The development of therapeutic strategies for the treatment of hemophilia A has been a long-lasting issue since the initial identification of the disease in the early 19th century and has involved several major steps to reach contemporary treatment. The current replacement therapy involving intravenous infusion of plasmatic or recombinant factor VIII (FVIII) has been efficient to control bleeding episodes of patients with hemophilia A. Nonetheless, replacement therapy requires frequent infusions to maintain values of FVIII above the threshold of efficacy and represents a serious burden that significantly impacts the patient's quality of life. The recent half-life extension technologies have permitted the development of a first generation of long-acting FVIII variants with improved circulating survival. These molecules, which are now in clinical phase III studies or have already received food and drug administration (FDA) approval for therapeutic use will allow a reduction in the frequency of infusion and lighten the treatment of hemophilia A. However, the half-life extension of FVIII was not as efficient as initially expected, particularly with regard to the results obtained with other therapeutic molecules. To overcome these limitations inherent to the nature of FVIII biology, several bypassing therapies independent of the FVIII molecule are currently in development. These emerging approaches exploit the modulation of the coagulation/anticoagulation balance taking place in the hemostatic process to compensate for the FVIII deficiency. In this review, we recount the history of hemophilia A treatment up to the recent emerging therapies, with particular focus on infusion-based strategies.

show abstract

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions

Galen

Engelen

Mauser‐Bunschoten

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Despite the discovery of a beneficial effect of systemically administered tranexamic acid and epsilon aminocaproic acid in preventing postoperative bleeding in people with haemophilia undergoing dental extraction, the limited number of randomised controlled trials identified, in combination with the small sample sizes and heterogeneity regarding standard therapy and treatment regimens between the two trials, do not allow us to conclude definite efficacy of antifibrinolytic therapy in oral or dental procedures in people with haemophilia. No trials were identified in people with Von Willebrand disease.

show abstract

Double-blind experiments on the effect of a peanut extract on the bleeding incidence in 92 haemophiliacs.

Cited by 11 publications

References 7 publications

Anti-fibrinolytic agents in bleeding disorders – A clinical perspective

Anti-fibrinolytic agents in bleeding disorders – A clinical perspective

Emerging Therapeutic Strategies in the Treatment of Hemophilia A

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions

Contact Info

Product

Resources

About